Livzon Pharmaceutical Group Inc.
LVZPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.63B
Close$
$15.41
195.2% upside
Current Fair Value
195.2% upsideUndervalued by 195.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.63 Billion |
|---|---|
| Enterprise Value | $1.65 Billion |
| Annual dividend | $0.21 |
| Dividend yield | 7.81% |
| Earnings per Share | $2.24 |
| Beta | 0.24 |
| Outstanding Shares | 887,907,171 |
Return
| Return on Equity | 11.88% |
|---|---|
| Return on Assets | 6.65% |
| Return on Invested Capital | 13.16% |
Valuation & Multiples
| P/E Ratio | 17.91 |
|---|---|
| PEG | -72.32 |
| Price to Sales | 0.47 |
| Price to Book Ratio | 0.35 |
| Enterprise Value to Revenue | 0.16 |
| Enterprise Value to EBIT | 0.84 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 2.58 |
| Debt to Equity | 0.33 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 24, 2026
EPS Estimate
$0.08
Consensus analyst estimateRevenue Estimate
$381.84 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$0.05
Consensus analyst estimateRevenue Estimate
$351.80 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Livzon Pharmaceutical Group Inc.
8,878 employees
CEO: Daping Liu
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturin...